Ferritin Nanocage TRAIL Trimer for Stable Cancer-Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing TRAIL proteins used as anticancer agents are unstable and have off-targeting issues, leading to rapid degradation and ineffective delivery to cancer cells.
Innovation Solution
A fusion polypeptide comprising a human TRAIL fragment, a triple helix linker, a rigid helix linker, and a human ferritin heavy chain fragment, along with a cancer-targeting peptide, is used to create a ferritin nanocage that stabilizes TRAIL as a trimer and enhances targeted delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRAIL protein is used as anticancer agent, then cancer cell apoptosis is induced, but stability and half-life in bloodstream are poor
Solution Approach 1:
The patent combines TRAIL protein with ferritin nanocage to form a fusion complex. The ferritin nanocage serves as a stable carrier that protects TRAIL from degradation in the bloodstream while maintaining its apoptosis-inducing capability. This merging resolves the contradiction by providing structural stability through ferritin while preserving TRAIL's biological function.
Solution Approach 2:
The invention creates a composite structure consisting of TRAIL protein displayed on the surface of ferritin nanocage. This composite material combines the stability and long circulation half-life of ferritin with the anticancer activity of TRAIL, simultaneously achieving both reliability and stability.
2Reliability
If TRAIL protein is administered, then apoptosis of cancer cells is induced, but off-targeting to normal cells occurs
Solution Approach 1:
The patent introduces cancer-targeting peptides at specific locations on the ferritin nanocage surface to enable selective recognition of cancer cells. This local modification allows the nanocage to differentiate between cancerous and normal cells, delivering TRAIL specifically to tumor sites while sparing healthy tissues, thus resolving the off-targeting issue.
Solution Approach 2:
The cancer-targeting peptide acts as an intermediary that mediates the interaction between ferritin nanocage and cancer cells. This intermediary component enables specific binding to cancer cell surface receptors, ensuring that TRAIL is delivered only to the intended target and preventing harmful effects on normal cells.
3Device complexity
If TRAIL is delivered as monomer, then delivery is simple, but binding activity to death receptor is insufficient
Solution Approach 1:
The patent merges multiple TRAIL monomers on the surface of a single ferritin nanocage to form functional trimers. This arrangement maintains the simplicity of delivering a single nanocage particle while ensuring that TRAIL is presented in the active trimeric form required for high-affinity binding to death receptors, thus resolving the contradiction between delivery simplicity and binding activity.
Solution Approach 2:
The invention nests multiple TRAIL molecules on the surface of the ferritin nanocage structure. This nested arrangement allows compact delivery of a single nanocage containing multiple active TRAIL units, achieving both simple delivery mechanics and high binding activity through the clustered presentation of TRAIL trimers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion protein effectively targets cancer cells, stabilizing TRAIL delivery and inducing apoptosis, with enhanced binding to TRAIL receptors and increased half-life in the bloodstream, resulting in improved anticancer efficacy.
Implementation Method 1
Ferritin is generally in the form of a hollow spherical cage in vivo, and the cage is composed of 24 subunits
Implementation Method 2
TRAIL (TNF-related apoptosis inducing ligand) is a protein inducing apoptosis by binding to TRAIL receptor
Implementation Method 3
a triple helix linker, a rigid helix linker
Implementation Method 4
TRAIL is a protein inducing apoptosis by binding to TRAIL receptor
Data Source
AI summary
A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.